Progenics Pharmaceuticals to Present at Needham Healthcare Conference

TARRYTOWN, N.Y., April 24, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) chief executive officer Mark R. Baker will make a presentation on Tuesday, April 30 at 3:00 PM EDT at Needham & Company's 12th Annual Healthcare Conference in New York City. The company overview will be webcast live via a link on the Events page of Progenics' website and archived there for 30 days.

About Progenics

Progenics Pharmaceuticals, Inc. develops innovative medicines for oncology, and has a pipeline that includes product candidates in preclinical through late-stage development. Progenics' first commercial product, Relistor® (methylnaltrexone bromide) for opioid-induced constipation, is marketed and in further development by Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. is developing the subcutaneous formulation. For additional information, please visit www.progenics.com.

Additional information concerning Progenics and its business may be available in press releases or other announcements and public filings made after this announcement.

(PGNX-G)

CONTACT: Amy Martini Corporate Affairs (914) 789-2816 amartini@progenics.com Kathleen Fredriksen Corporate Development (914) 789-2871 kfredriksen@progenics.com

Source:Progenics Pharmaceuticals Inc.